Teva beats Copaxone forecasts; Bayer HealthCare churns up 19% sales growth;

@FiercePharma: Investors cheer Abaxis but trounce IDEXX on quarterly diagnostics performance. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: IOYMI: Napp Pharmaceuticals says it is offering England's NHS Remsima for as much as 60% less than Remicade. Article | Follow @EricPFierce

@CarlyHFierce: GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surge. Article | Follow @CarlyHFierce

> Teva ($TEVA) beat profit forecasts and raised its outlook on Thursday, in part thanks to a revenue beat from multiple sclerosis med Copaxone. Report

> Bayer's healthcare unit once again drove the German company's sales, with 19.2% growth in that business, to €5.65 billion, overshadowing currency setbacks in its CropScience unit. Report

> Backers of a referendum targeting a reduction in prescription drug costs in California said Wednesday that they'd rounded up more than enough signatures to place their measure on the November 2016 ballot. Report

Medical Device News

@FierceMedDev: Cleveland Clinic developing catheter for delivery of chemotherapy directly into the brain. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Theranos authorized new shares that would value the co. at $10B, 3 days before the WSJ article came out. Story | Follow @EmilyWFierce

> Startup Qvella gets $20M Series A to develop rapid pathogen detection test. Story

> Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. News

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Interesting that most of the $PFE/$AGN discussion is around the mechanics of a deal, rather than a backlash against another megamerger. | Follow @JohnCFierce

> Frazier unveils a $262M pure-play biotech venture fund. Story

> Biotech IPOs are staggering as the bulls begin to fade back. Report

> Ultragenyx launches an RNA collaboration with upstart Arcturus. Article

CRO News

> Icon ekes out another quarter of growth despite currency woes. More

> INC boosts its outlook after another big revenue quarter. Report

> Parexel's profits slide as it slashes costs. Story

> Novartis, Qualcomm back trial startup's $6.5M round. Item

> PRA upgrades its Dutch R&D hub with eyes on bioanalytics. Article

Pharma Manufacturing News

> Pfizer and GSK to work together on continuous manufacturing. Item

> Novartis' Sandoz plants in India cited in warning letter. More

> Saline producers face call for FTC probe into shortage, rising prices. Report

> States want FDA to quit seizing their execution drugs. Story

> Aurobindo moves forward with plans for new U.S. plant. Article

Pharma Asia News

> Novartis to close one Indian manufacturing plant as FDA warning bites. Article

> Lupin hopes for more U.S. approvals as earnings drop 35%. Item

> Health insurance companies still being targeted by Chinese hackers. Story

> Cough syrup abuse gets India's attention. More

> BMS sees sharper hep C competition in Japan in Q3. Report

And Finally... Former Merck & Co. ($MRK) CEO Roy Vagelos has amassed a net worth of $1.3 billion from his service on fast-growing Regeneron's board. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.